KeyCorp Raises Becton Dickinson and (BDX) Price Target to $273.00

Becton Dickinson and (NYSE:BDX) had its target price upped by analysts at KeyCorp from $264.00 to $273.00 in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. KeyCorp’s price objective would suggest a potential upside of 12.23% from the company’s previous close.

A number of other research analysts have also commented on BDX. Piper Jaffray Companies decreased their price objective on Becton Dickinson and to $250.00 and set an “overweight” rating on the stock in a report on Tuesday. Barclays set a $260.00 price objective on Becton Dickinson and and gave the company a “hold” rating in a report on Thursday. Wells Fargo & Co reduced their target price on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating on the stock in a report on Wednesday. Citigroup increased their target price on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, Royal Bank of Canada reissued a “hold” rating and set a $248.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $254.07.

NYSE BDX traded down $1.22 on Thursday, reaching $243.26. The stock had a trading volume of 1,005,699 shares, compared to its average volume of 1,421,737. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. Becton Dickinson and has a 1-year low of $209.91 and a 1-year high of $265.87. The firm has a market cap of $63.38 billion, a price-to-earnings ratio of 22.09, a P/E/G ratio of 1.46 and a beta of 1.19.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting analysts’ consensus estimates of $2.93. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same period in the prior year, the firm posted $2.40 EPS. The company’s revenue for the quarter was up 39.0% on a year-over-year basis. On average, equities analysts anticipate that Becton Dickinson and will post 12.2 earnings per share for the current fiscal year.

In other news, EVP James C. Lim sold 5,189 shares of the stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the sale, the executive vice president now directly owns 13,318 shares of the company’s stock, valued at approximately $3,227,750.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Timothy M. Ring sold 42,000 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total value of $9,956,940.00. Following the sale, the director now directly owns 93,688 shares in the company, valued at $22,210,614.16. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in BDX. Fundsmith Equity Fund L.P. bought a new stake in shares of Becton Dickinson and during the 2nd quarter worth $894,775,000. FMR LLC lifted its position in shares of Becton Dickinson and by 13.7% during the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock worth $4,069,559,000 after buying an additional 2,049,874 shares during the last quarter. Charles Schwab Investment Advisory Inc. bought a new stake in shares of Becton Dickinson and during the 2nd quarter worth $291,167,000. Vontobel Asset Management Inc. lifted its position in shares of Becton Dickinson and by 823.0% during the 2nd quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplier’s stock worth $250,205,000 after buying an additional 904,097 shares during the last quarter. Finally, Cornerstone Wealth Management LLC lifted its position in shares of Becton Dickinson and by 233.6% during the 3rd quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock worth $3,286,000 after buying an additional 453,623 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Story: How to Invest in Marijuana Stocks

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply